Bagsværd, Denmark, 13 October 2023 – Novo Nordisk  (NYSE: NVO) today announced that the sales and operating profit growth at constant exchange rates (CER) for the first nine months of 2023 and that the full-year sales and operating profit outlook at CER have been raised.

In the first nine months of 2023, Novo Nordisk’s sales increased by 33% and operating profit increased by 37% both at CER.

The sales outlook for 2023 is updated, primarily reflecting higher full-year expectations for Ozempic^® volumes sold in the US and gross-to-net sales adjustments for Ozempic^® and Wegovy^® in the US.

Novo Nordisk’s full disclosure of the financial results for the first nine months of 2023 will be published on 2 November 2023.

The above expectations are based on assumptions including those described on pages 15 and 16 of the Financial report for the period 1 January 2023 to 30 June 2023 (Company Announcement No 52/2023).

The forward-looking statements on page 22 of the Financial report for the period 1 January 2023 to 30 June 2023 (Company Announcement No 52/2023) also apply to this company announcement.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 59,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.